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Abstract  The  zika  virus,  another  re-emerging  Flavivirus  transmitted  to  humans  by  mosquitoes,
is responsible  for  the  most recent  fever  outbreak  in the  Americas  and  the Pacific,  starting  in
2015. The  immunologically  naïve  population  in the  Americas  favors  the  spread  of  epidemics.  The
zika fever  is characterized  by  febrile  illness,  malaise,  conjunctivitis  and  a maculopapular  rash.
Similar to  other  arboviroses  recently  spread  in the  Americas,  there  is no specific  or  effective
antiviral therapy  and  vaccines  are  still  in trials.  The  only  effective  preventive  measures  consist
of individual  protection  against  mosquito  bites  and  vector  control.  This  febrile  illness  increases
the epidemiological  and public  health  challenge  existing  in America,  where  the  population  is
already fighting  against  dengue  and  chikungunya  fever.  Disease  prevention  is important  due  to
the economic  burden  it  entails.  The  fact  of  sexual  and  transfusion  virus  transmission  is a  great
challenge to  overcome.  Doctors  need  to  distinguish  between  dengue,  chikungunya  and  other
diseases to  give  a  successful  treatment  and  prevent  the disease  spreading.
© 2016  Published  by  Masson  Doyma  Me´xico  S.A.  on  behalf  of  Universidad  Auto´noma  de Nuevo
Leo´n.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
∗ Corresponding author at: Servicio de Infectología, Facultad de
Medicina y Hospital Universitario ‘‘Dr. José Eleuterio González’’,
Universidad Autónoma de Nuevo León, Ave. Francisco I.  Madero
and Ave. Gonzalitos s/n, Col. Mitras Centro, 64460 Monterrey, N.L.,
Mexico.
E-mail address: javramos31@gmail.com (J. Ramos-Jiménez).
Introduction
Among  many  public health  alerts,  the global  spread  of
arboviruses  is  of  concern  and  alarm.  The  Zika virus  is  trans-
mitted  to  people  through  the  bite of  an infected  mosquito
from  the  Aedes  genus,  mainly  Aedes  aegypti  in tropical
and  subtropical  regions  and  Aedes  albopictus  in  temper-
ate  climates.  These  are the same  mosquitoes  that  transmit
dengue,  Chikungunya  and  yellow  fever.  The  disease  is  named
Zika virus  disease  (ZVD)  instead  of  Zika fever  because  of
the  frequent  subfebril  and  afebrile  manifestations.  Last,
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but  not least  important,  the Zika virus  is  the  third recent
global  infectious  disease  outbreak,  following  closely  behind
H1N1  flu  and the  Ebola  virus,  which  has  had  detrimental
implications  for  pregnant  women  and their  unborn  children.
Epidemiology
The  first  isolation  was  made  in  April  1947  from  the serum
of  a  pyrexial  rhesus  monkey  in  the  canopy  of Zika  for-
est,  Uganda,1 followed  by  an isolation  from  Aedes  africanus
mosquitoes  in January  1948, in the  same  forest.  The  first
human  cases  were detected  in Uganda and the United
Republic  of Tanzania  in 1952,  where  neutralizing  antibodies
to  the  Zika virus  were detected  in  sera.2,3 A couple of years
later,  in  1954,  the virus  was  isolated  from  a girl  in  Eastern
Nigeria.4
From  the  1960s  to  the 1980s,  the  zika  virus  was  detected
in  mosquitoes  and  sentinel  rhesus  monkeys  in countries  of
equatorial  Africa.  Sporadic  human  cases  were  identified,
mostly  by  serological  methods,  but  such  cases  were  rare  and
the  disease  was  regarded  as  benign.
In  1969,  the Zika  virus  expanded  its  geographical  distri-
bution  in  equatorial  Asia, where  it is  the first  large  outbreak
in  humans  on  the Pacific  island  of Yap, in the  Federated
States  of  Micronesia.  An  estimated  73%  of  Yap  residents  over
three  years  of  age  were  infected  with  the  Zika  virus.  No
deaths,  hospitalizations,  or  neurological  complications  were
reported.
From  2012  to 2014,  the Zika  virus  caused  outbreaks
in  French  Polynesia,  Easter Island,  Cook  Islands  and New
Caledonia.  Meanwhile,  the  virus  continued  circulating  in
Cambodia,  Malaysia,  Thailand,  Nigeria,  Senegal  and  Uganda.
By  March  2015,  an  illness  characterized  by  a  skin  rash  was
detected  in northern  Brazil.  Nevertheless,  it  was  not  until
May  when  the Zika  virus  infection  was  confirmed.  By July,
Brazil  reported  laboratory-confirmed  Zika  cases in twelve
states.  In  October  2015, Colombia  reported  PCR-confirmed
patients  with  locally  acquired  Zika  infections  and  poste-
riorly  156  confirmed  cases  in thirteen  municipalities.  The
Zika  virus  was  limited  to  Brazil  and Colombia  until  Novem-
ber  2015,  when  it spread  to  Suriname,  Guatemala,  Mexico,
El  Salvador,  Paraguay  and Venezuela.  In  December,  Panama
reported  its  first  confirmed  cases,  as  well  as  Haiti,  Puerto
Rico,  Martinique,  Honduras  and French  Guiana.5
In January  2016,  Bolivia  and  Saint  Martin  detected  their
first  indigenous  cases,  as  well  as  Barbados,  U.S.  Virgin
Islands,  Dominican  Republic,  Nicaragua  and  Jamaica.6 As
of  April  28,  2016, the new  countries  with  confirmed  local
transmissions  are:  Curacao,  Costa  Rica,  Republic  of  Trinidad
and  Tobago,  Aruba,  Bonaire,  Sint  Maarten,  Saint  Vincent  and
the  Grenadines,  Dominica,  Cuba,  Saint  Lucia  and Belize.
This  makes  a  total  of  35  countries/territories  with  ongoing
autochthonous  Zika  virus  transmission  and 7982  accumu-
lated  confirmed  cases.7
In Mexico,  the first  imported  case  was  identified  in
November  17,  2015,  when  a traveler  came  back  from
Colombia  to  Querétaro.  Later  in that  month,  in the 47th
Epidemiological  Week,  the first  two  cases  were  reported  in
Monterrey,  Nuevo  León,  and  in Huixtla,  Chiapas.  None  of  the
patients  had traveled  recently.8 New  cases were  detected
until  the  52nd  Epidemiological  Week  in Jalisco,  Chiapas  and
Nuevo  León.9 The  first  Epidemiological  Week  of  2016  lacked
confirmed  cases.  However,  Chiapas  has  been  reporting  new
cases  since  the  2nd  Epidemiological  Week.10 Up  to  April  29,
2016,  there  have  been  185 confirmed  autochthonous  cases
in  Mexico  reported  from  the states  of  Chiapas,  Guerrero,
Jalisco,  Michoacán,  Nayarit,  Nuevo  León, Oaxaca,  Sinaloa,
Tabasco,  Veracruz  and  Yucatán.11
Even  though  there  is  no  autochthonous  ongoing  transmis-
sion  in  the  United  States,  the presence  of  Ae. albopictus
in  a great  proportion  of  the continental  US  poses  a risk  for
autochthonous  Zika virus  transmission.12 The  geographic  dis-
tribution  of  the autochthonous  transmission  of  the Zika virus
can  be observed  in Fig.  1.
Molecular virology
The  Zika  virus  is  a member  of  the  Flavivirus  genus  of  the
Flaviviridae  family.  This  virus  is  related  to  other  pathogenic
vector  borne  Flavivirus,  where  we  can  find  the  Dengue  virus,
the West  Nile  Virus  and  the Saint  Louis encephalitis  virus.  It
is  a single-stranded,  positive-sense,  RNA  virus  with  a genome
approximately  11  kb  in length.13 The  single  open  reading
frame  (ORF)  encoding  a  polyprotein  is  framed  by  5′ and
3′ untranslated  regions.  The  encoding  polyprotein  is  trans-
lated  and  processed  by  viral and cellular  proteases,  co-  and
post-translationally,  into  three  structural  (capsid,  precursor
membrane  or  membrane,  and  envelope)  and  seven  nonstruc-
tural  (NS1,  NS2a,  NS2b,  NS3,  NS4a,  NS4b,  and  NS5)  proteins
(Fig.  2).  The  NS1,  NS3  and NS5  proteins  are large and highly
conserved,  meanwhile  the NS2A,  NS2B,  NS4A  and  NS4B  pro-
teins  are  small  and  hydrophobic.14
After  a  mosquito  bite,  the Zika  virus  can  infect  human
dermal  fibroblasts,  epidermal  keratinocytes  and  imma-
ture  dendritic  cells.  AXL,  a phosphatydylserine  receptor,
has  been  described  as  a ZIKV  entry  receptor  and  is  also
related  with  cellular  autophagy,  enhancing  ZIKV  replication
in  permissive  cells.  DC-SIGN,  Tyro3 and TIM-I  also  seem  to
mediate  ZIKV entry.15 Information  concerning  ZIKV replica-
tion  is  scarce;  therefore  we  present  the common  features
of  the Flaviviridae  family  life  cycle.  After  the  viral parti-
cle interacts  with  the  host  receptors,  it is  internalized  by
clathrin-mediated  endocytosis.  The  low  pH of  the  endo-
some  induces  fusion  of the virion  envelope  with  cellular
membranes.  Following  uncoating  of  the  nucleocapsid,  the
RNA  genome  is  released  into  the cytoplasm.  The  genome
serves three  discrete  roles  within  its  life  cycle:  as  the mes-
senger  RNA  (mRNA)  for  translation  of all viral  proteins,  a
template  during  RNA replication,  and  the  genetic  material
packaged  within  new  virus  particles.  RNA  replication  occurs
entirely  in  the  cytoplasm  in close  association  with  intracel-
lular  membranes.  Progeny  virions  assemble  by  budding  into
an  intracellular  membrane  compartment,  most  likely  the
endoplasmic  reticulum  (ER),  then  transit  through  the host
secretory  pathway  and  are released  at the cell  surface.16
Phylogenetic  analysis  among  the  genus  Flavivirus  places
ZIKV  at clade  X, with  the Spondweni  virus,  in  the mosquito-
borne  cluster.17 Recent  phylogenetic  analysis  divides  ZIKV
into  three  different  lineages:  West  African,  East  African
and  Asian.  The  three  distinct  ZIKV lineages  share  a com-
mon  ancestor,  possibly  with  Ugandan  lineages  around  1920.18
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Figure  1  Countries  and  regions  in the  Americas  with  autochthonous  Zika  virus  transmission  and  complications.  The  map  illus-
trates the  countries  and regions  where  autochthonous  Zika  virus  transmission  is taking  place.  It also  shows  the  countries  where
Guillain--Barré  syndrome  cases were  reported,  as well  as  confirmed  microcephaly  cases.  Mexico  and Brazil  are divided  by  states.
The Brazilian  state  names  are  in italics.  Latin  and  Non  Caribbean  are  not  labeled  due  to  the  map  resolution.  Information  updated
April 28,  2016.  ZIKV:  Zika  virus;  GBS:  Guillain--Barré  syndrome.
Source:  World  Health  Organization,52 Pan  American  Health  Organization,7 and Secretarias  de  Saúde  dos  Estados  e  Distrito  Federal.46
The  Asian  lineage  is  responsible  for  the current  outbreak  in
America.19
Transmission
Vector  transmission
The  Zika  virus  is  mostly  transmitted  to  people  through
the  bite  of an infected  mosquito  from  the Aedes genus,
including  Aedes  aegypti  in  tropical  and  subtropical  regions
and  Aedes  albopictus  in temperate  regions.  Given  numerous
virus  isolations  from  mosquitoes,  they  are clearly  the natu-
ral  reservoirs.  Vertebrate  hosts  are most  likely  amplifying  or
dead-end  hosts,  since  no  vertebrate  in nature has  ever  been
conclusively  determined  to  serve  as  a true reservoir  for  any
arbovirus.20
Some  of the  prevalent  vectors  identified  in Africa  include
Ae.  luteocephalus, Ae.  africanus,  and  Ae.  furcifer.  Never-
theless,  the  dominant  species  varies considerably  depending
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Figure  2  Zika  virus  genome  organization.  The  figure  shows  the  structural  and  nonstructural  proteins  the  way  they are organized
throughout  the  genome  as  well  as  the untranslated  regions  in 5′ and  3′.  The  name,  size  in amino  acids  and  function  is showed  for
each protein.  The  figure  is drawn  to  scale  based  on the  reference  ZIKV  genome  with  GenBank  access  number:  NC  012532.1.13 The
information regarding  viral  protein  function  was  obtained  from  the  UniProt  database  using  dengue  virus  due  to  the  lack  of  published
data. The  accession  number  used  was  P17763.77 NS:  nonstructural  protein;  C:  capsid;  E:  envelope;  prM:  precursor  membrane;  UTR:
untranslated region;  Kb:  kilobases.
on  sampling  location.  Interestingly,  the  involvement  of Ae.
aegypti  has been  small in Africa.21 On the other  hand,  Ae.
aegypti  has  been  the  single  most  important  vector  in South-
east  Asia  and the Pacific.  In  the  outbreak  on Yap  Island  in  the
Pacific,  Ae.  hensilli  was  implicated  as  a  possible  vector.22
Ae.  albopictus  is  also  susceptible  to  infection  and able
to  transmit  ZIKV.23 The  highest  concern  is  that  Ae. albopic-
tus  has  been  found  in temperate  climates  where  Ae. aegypti
is  absent,  allowing  virus  transmission  in  those  regions.  This
includes  37  of  48  contiguous  states  of  the  United  States
of  America,  Albania,  Bulgaria,  Croatia,  Southern  France,
Greece,  Italy,  Malta,  Montenegro,  Slovenia,  Eastern  Spain,
and  Southern  Switzerland.24,25
Non-vector  transmission
Even  though  the  main  transmission  route  of  the  Zika  virus
is  by  the  bite of  an infected  mosquito,  cases  of non-vector
transmission  have been  reported.
During  the  French  Polynesian  outbreak,  3% of  1505
blood  donors,  asymptomatic  at the  time  of  blood  dona-
tion,  were  found  positive  for  ZIKV  by  PCR.26,27 In this  recent
outbreak,  two  possible  cases of  transfusion--transmission
have  been  described  in  Campinas,  Brazil  and  are being
investigated.28 For these  reasons,  the  Food  and  Drug  Admin-
istration  (FDA)  has  made  recommendations  to  prevent
transfusion--transmission.  Some  of  these recommendations
are:  defer  donors  at risk  for  ZIKV  infections  for 4  weeks,
use  of an FDA-approved  pathogen  reduction  device,  and
test  local  blood  donations  with  an  FDA-licensed  blood  donor
screening  test  for ZIKV when available.29 However,  a  recent
publication  affirmed  that screening  potential  blood  donors
based  on  symptoms  or  serological  testing  of donated  blood
would  do  little  to  protect  the  blood  supply,  reducing  the
risk  of  an infected  donation  by  at  most  30%.  The  authors
advise  that  high  incidence  areas  should consider  PCR  testing
to  identify  safe components  for  use  in pregnant  women.30
In addition,  the Zika  virus  can  be  sexually  transmitted
from  a  man  to  his  sex partner(s).  During  February  2016,  the
CDC  received  reports  of 14  instances  of  suspected  sexual
transmission  of  the  Zika  virus.  Among  these,  two  laboratory-
confirmed  cases  and  four probable  cases of  the  Zika  virus
disease  have been  identified  among  women  whose  only
known  risk  factor  was  sexual  contact  with  a  symptomatic
male  partner  with  recent  travel  to  an area  with  ongoing  Zika
virus  transmission.31 To  date,  all reported  cases  of  sexual
transmission  of the Zika  virus  have  been  from  symptomatic
male  partners.  Sexual  transmission  of  the  Zika  virus  from
infected  women  to  their  sex  partners  and  from  persons
who  are  asymptomatically  infected  has  not  been  reported.31
There  have  been  two  reports  of  replication-competent  Zika
virus  isolated  from  semen  at least 2 weeks  after  onset  of
illness,  when  blood  plasma  specimens  were  negative  by RT-
PCR.32,33 Viral  ARN  has been  detected  in  semen  by  RT-PCR  as
long  as 62  days  after  illness  onset,  but  the duration  of persis-
tence  of  infectious  Zika virus  in semen  remains  unknown.34
There  is  now  a  report  that  indicates  that  the Zika virus  can  be
transmitted  through  anal  sex,  as  well  as  vaginal  sex.35 There-
fore,  the  Centers  for  Disease  Control  and  Prevention  issued
interim  guidance  for  the  prevention  of  sexual  transmission
of  the Zika  virus.  Couples  in which  a woman  is  pregnant
should  use  condoms  or  abstain  from sex  for  the duration
of  the pregnancy.  Likewise,  couples  in which  a man  had  a
confirmed  Zika virus  infection  or  clinical  illness  should  con-
sider  using  condoms  or  abstaining  from  sex  for  at least  6
months  after  onset of illness.  If the  couple  lives  in an  area
with  active  Zika virus  transmission,  the  use  of  condoms  or
abstaining  from  sex  while  active  transmission  persists  are
recommended.36 Evidence  implies  trans-placental  transmis-
sion  and  perinatal  transmission  during  delivery,  with  Zika
virus  RNA  being  found  in amniotic  fluid  and  in paired  blood
samples  taken  from  newborn  infants  and  mothers.37,38 There
is  no  evidence  to  support  transmission  by  breastfeeding  or
via  contact with  saliva,  urine,  or  respiratory  droplets.
Clinical  features
The  first  clinical  characterizations  described  Zika  virus
infections  as  mild  and  self-limiting.
After  an  experimentally  induced  Zika  virus  infection  in
a  human  volunteer,  it resembled  the condition  observed  in
the  girl in  Eastern  Nigeria  reported  by  MacNamara  closely.4
The  infection  was  a  short-term  fever,  without  evidence
of  involvement  of  any particular  tissue.  In both  cases  the
only  manifestations  were  fever  and headache.39 The  clinical
Documento descargado de http://www.elsevier.es el 25-08-2016
The  Zika  virus  disease  119
Table  1  Differential  diagnostic  of  most  common  arbovirus  infections  in  acute  presentations.
Signs  and  symptoms  ZIKV  (%)  CHIKV  (%)  DENV  (%)  YFV  (%)  WNV  (%)
Fever  65  89  90.6  72  95
Headache 45  47  57.7  54  65
Myalgia 48  60  54.6  36  35
Arthralgia 65  96.1  37.5  ND  35
Arthritis Rare  31.8  3.8  ND  ND
Retroocular  pain  39  Rare  41.4  ND  ND
Non-purulent  conjunctivitis  55  Rare  7.7  ND  ND
Lymphadenopathy  45  8.9  Rare  ND  ND
Rash 90  40.1  7 ND  5
Signs of  bleeding Rare  6.4  8.3  36  ND
Neurologic  signs Rare  12.1  6 ND  35
Nausea/vomit  10  47  32  30  45
Edema 19  Rare  14.4  ND  ND
Jaundice ND  ND  Rare  34  ND
Source:  Duffy,22 Pialoux,72 Borgherini,73 Allonso,74 Romano,75 and Riabi.76
ZIKV: Zika virus; CHIKV: chikungunya virus; DENV: dengue virus; YFV: yellow fever virus; WNV: West Nile virus; ND: no  data.
picture  of the infection  described  by  a  worker  that  was
infected  collecting  mosquitoes  in the  Zika  forest  was  that
of  a  mild  febrile  illness  of  short  duration  accompanied  by
a  generalized  maculopapular  rash.40 In  Java,  Indonesia,  all
patients  had  high  fevers  upon  examination.  Six  of  seven
patients  had  stomach  ache,  five  had  malaise,  five  expe-
rienced  dizziness  and  four  were  anorexic.  Less  frequently
reported  symptoms  and  signs  were  diarrhea,  constipation,
hypotension  and  chills.  Interestingly,  arthralgia,  myalgia,
vomiting,  conjunctivitis,  hematuria,  lymphadenopathy  and
leg  pain  were  present  in one  of the  patients.  Furthermore,
none  of the patients  had  a rash.41 At  a study  made in  Thai-
land  with  cases  from  2012  to  2014,  the  clinical  presentation
was  mild  and  nonspecific.  All  subjects  presented  fever  and  a
maculopapular  rash.  Other symptoms  included  sore  throat,
arthralgia,  myalgia,  rhinorrhea,  and  headache.  Only  two
patients  complained  of  conjunctivitis,  which was  less  than
the  rate  previously  reported  in  ZIKV cases  outside  Africa.42
The  incubation  period  of  the  Zika  virus  disease  is not
clear,  but  is estimated  to  be  4--7  days.30 The  symptoms
are  similar  to  other  arbovirus  infections  such as  dengue,
and  include  fever,  maculopapular  rash, pruritus,  conjunc-
tival  hyperemia,  myalgia,  arthralgia,  malaise,  headache,
retro-orbital  pain  and  digestive  disorders.  These  symptoms
are  usually  mild  and last  for  2--7  days.22,43 In addition,
common  presentations  accompanying  the  febrile  illness  are
frequently  confused  with  dengue  virus  infection,  which  may
result  in  underreporting  of  Zika virus  infection.  In Table  1,
we  present  the frequent  signs and  symptoms  of  the most
common  arboviroses.  This  can  be  of great  help  to  clinicians
regarding  differential  diagnosis.
Complications
When  Zika  virus  infections  were  first  noted,  there  were  no
reports  of  complications,  but  in recent  ZIKV  outbreaks  the
incidence  of  neurological  disorders  has  increased.  Evidence
that  neurological  disorders,  including  microcephaly  and
Guillain--Barré  syndrome,  are linked  to  Zika  virus  infection
remains  circumstantial,  but  a  growing  body  of  clinical  and
epidemiological  data  points  toward  a causal  role  for  the Zika
virus.
Microcephaly
There  are 6  countries,  territories  and areas  reporting
microcephaly  cases  potentially  associated  with  Zika virus
infection.  These  are Brazil,  Cabo  Verde,  Colombia,  French
Polynesia,  Martinique,  and  Panama  (Fig.  1).44
According  to  the Ministry  of  Health  of  Brazil,  from  Octo-
ber  22,  2015  through  April  23,  2016,  there  have  been  reports
of  7228  suspected  cases  of  microcephaly  or  other  nervous
system  malformations  among  newborns  across  the country.
This  contrasts  with  the period  from  2001  to  2014,  when an
average  of  163  microcephaly  cases  was  recorded  nationwide
per  year.45 Up  to  April  23,  2016,  Brazil  Health  authorities
have  reviewed  3518  cases,  49%  of  the total.  They  iden-
tified  1198  confirmed  cases of  microcephaly  and/or  other
central  nervous  system  (CNS)  malformations  with  evidence
suggestive  of congenital  infection,  and  discarded  2320.46
The  1198  confirmed  microcephaly  cases  occurred  in 435
municipalities  located  in 22  Brazilian  Federal  Units:  Alagoas,
Bahia,  Ceará,  Maranhão,  Paraíba,  Pernambuco,  Piauí,  Rio
Grande  Do  Norte,  Sergipe,  Espírito  Santo,  Minas  Gerais,  Rio
de  Janeiro,  Amapá,  Amazonas,  Pará,  Rondônia,  Distrito  Fed-
eral,  Goiás,  Mato Grosso,  Mato  Grosso  Do Sul,  Paraná,  and
Rio  Grande  Do Sul.46 There  have been  251 deaths (includ-
ing  miscarriages  or  stillbirths)  reported  among  microcephaly
and/or  CNS  malformation  cases.  Fifty-four  of these deaths
were  confirmed  as  having  microcephaly  and/or  CNS  mal-
formation,  167  remain  under  investigation  and  30  were
discarded.46 There  is  evidence  that  in addition  to  micro-
cephaly,  there  may  be a  link  between  Zika  virus  infection
and hydrops  fetalis  and  fetal demise.47
A recent  article  reports  an increase  in  congenital  cere-
bral  malformations  and  dysfunction  in fetuses  and  newborns
in  French  Polynesia,  following  an  epidemic  of  the Zika  virus,
from  October,  2013  to  March, 2014.  A  retrospective  review
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identified  19  cases,  including  eight  with  major brain  lesions
and  severe  microcephaly,  six with  severe  cerebral  lesions
without  microcephaly  and  five  with  brainstem  dysfunction
without  visible  malformations.  Of  the  five-microcephaly
cases  that  were  tested  virologically,  viral  ARN  was  detected
by  RT-PCR  and  infectious  ZIKV  isolates  were  obtained  in
four.  When  interviewed,  the mothers  of four  cases  reported
clinical  infection  in the first  trimester  of  pregnancy.  The
remaining  mother  could  not be  reached.48
A  case  series  of  pregnant  U.S.  women  that  traveled  to
Zika  affected  areas  reported  that  infection  during  pregnancy
was  associated  with  a  range  of  outcomes,  including  early
pregnancy  losses,  congenital  microcephaly,  and apparently
healthy  infants.  In  addition,  viral  RNA  was  detected  in  fetal
remains  of early  pregnancy  loss,  amniocentesis  fluid,  and
placenta.49
On  March  30th,  Colombia  reported  50  live  births  with
microcephaly  between  January  4th,  2016  and  March  20th,
2016.  Of the  50  cases  registered,  16  were  discarded  for
microcephaly  with  suspected  association  with  the Zika  virus.
Of  the  remaining  34  cases,  two  were  ruled  out for  not  meet-
ing  the  national  criteria  for  association  with  microcephaly  by
Zika  virus.  The  remaining  cases (32)  are  under  investigation.
So  far,  eight  of  these  32  cases of  microcephaly  presented
positive  Zika  virus  results  by  RT-PCR.44
A  recent  study  from  Pernambuco,  Brazil,  established  that
30  of  31  studied  microcephaly  cases  had Zika-specific  IgM in
their  CSF.  Since  IgM  does not  cross  either  the placenta  barrier
or  the  blood--brain  barrier, the presence  of IgM in the  CSF
indicates  that  the neonate  had  the infection  in the  CNS.  This
is  strong  evidence  that  microcephaly  was  a  consequence  of
Zika  virus  infection.50
A  group  of  researchers  evaluated  the available  data
regarding  ZIKV  and microcephaly  using  criteria  that  have
been  proposed  for  the assessment  of  potential  teratogens.
They  concluded  that there  is  a causal  relationship  between
prenatal  Zika  virus  infection  and microcephaly  and  other
serious  brain  anomalies.51
The  link  between  ZIKV  infection  and  microcephaly
becomes  stronger  with  every  new  case  report  published.
However,  case  reports,  unlike  cohort  studies,  do not  estab-
lish  a  causative  link  between  the virus  and  microcephaly.
More  research  is needed  to  clearly  establish  the relationship
between  ZIKV  infection  and  microcephaly.
Guillain--Barré syndrome
According  to  the WHO,  during 2015  and  2016,  thirteen
countries  and  territories  have  reported  an  increased  inci-
dence  of  Guillain--Barré  syndrome  (GBS)  and/or  laboratory
confirmation  of  a Zika  virus  infection  among  GBS  cases.52
Countries  where  there  is  increased  incidence  of  GBS
cases,  with  at least one GBS case  with  confirmed  Zika
virus  infection  are:  Brazil,  Colombia,  Dominican  Republic,
El  Salvador,  French  Polynesia,  Honduras,  Suriname,  and
Venezuela.  In  contrast,  the countries  reporting  GBS  with
laboratory  confirmed  Zika  virus  infections  without  increase
of  GBS  incidence  are:  French  Guiana,  Haiti,  Martinique,
Panama  and Puerto  Rico.52 Countries  or  territories  where
GBS  cases  were  reported  can  be  seen  in Fig.  1.
There  is  little  information  in  respect  to  the clinical  char-
acteristics  of  the Guillain--Barré  syndrome  cases  caused
by  this  virus.  The  most  complete  description  is  from  a
case-control  study  made  in French  Polynesia,  where  they
diagnosed  42  cases  of Guillain--Barré  syndrome.  Forty-one
(98%)  patients  had  anti-Zika  virus  IgM or  IgG,  and  all  (100%)
had  neutralizing  antibodies  against  the Zika  virus.53
Most  patients  had  electrophysiological  findings  compati-
ble  with  the acute  motor  axonal  neuropathy  (AMAN)  type  of
the  syndrome,  and  had  rapid evolution  of  the disease.53 The
clinical  outcome  of  these  patients  with  the Zika  virus  and
Guillain--Barré  syndrome  was  generally  favorable,  despite
a  rapid  onset  and short  plateau  phase, as  may  be  seen
in other  patient  groups  suffering  from  the  AMAN type  of
Guillain--Barré  syndrome.  Even  though  it is  very  likely  that
these  patients  had  been  recently  infected  with  the Zika
virus,  it is  possible  that  the disease  was  due  to  dengue  or
might  possibly  have been  unrelated  to  Flavivirus  infection.53
A recent  case  report  showed  that  a housekeeper  from
Rio  de Janeiro  that  presented  clinical  features  consistent
with  paraparetic  Guillain--Barré  syndrome,  had  a  positive
PCR  test  for  ZIKV  in serum,  cerebrospinal  fluid,  saliva  and
urine.  It  is  noteworthy  that  the  patient’s  serum  and  cere-
brospinal  fluid were negative  for  dengue  and  chikungunya  by
real-time  PCR.54 This  study  helps  to confirm  the association
between  ZIKV and  GBS.
Substantial  new  research  has  strengthened  the  associ-
ation  between  the Zika  infection  and  the occurrence  of
neurological  disorders.55 However,  more  investigation  is
needed  to  better  understand  this relationship.  Confound-
ing  factors  include  the  contemporary  circulation  of  dengue
and  chikungunya  in  the  Americas,  which  are transmitted  by
the  same species  of mosquito.
Clinical and laboratory diagnosis of Zika
Even  though  the  Zika  virus  was  discovered  decades  ago,
there  are no  licensed  or  broadly  distributed  diagnostic  tests.
According  to  the WHO,  a  suspected  case  of  Zika  virus  disease
is  defined  as  a  patient  with  a  rash  and two  or  more  of the
following  signs or  symptoms:  fever,  usually  <38.5 ◦C,  con-
junctivitis  (non-purulent/hyperemic),  arthralgia,  myalgia,
and/or  peri-articular  edema.  A arobable  case  of  Zika  virus
disease  is  a  patient  who  meets  the criteria  of a suspected
case  and  has  Zika  IgM antibodies,  with  no  evidence  of  infec-
tion  with  other  flaviviruses.  A confirmed  case  of  Zika  virus
disease  is  a patient  who  meets  the criteria  for  a suspected
case  and  has laboratory  confirmation  of  recent  Zika  virus
infection.  This  confirmation  can  be the following:  viral  RNA
(serum,  urine,  saliva,  tissue  or  whole  blood),  positive  Zika
IgM antibodies  and plaque  reduction  neutralization  (PRNT90)
for  Zika  virus  titers  ≥20  and four (or  more)  times  greater
than  the titers  for  other  flaviviruses,  with  the  exclusion  of
other  Flaviviruses.  In autopsy  specimens,  detection  of  the
viral  genome  should  be by  molecular  techniques,  or  antigen
detection  by immunohistochemistry.56
Unfortunately,  if the Zika  virus  disease  is  suspected  in a
population  where  other  flaviviruses  are endemic,  serolog-
ical  diagnosis  of  ZIKV  is  difficult  to  interpret  because  the
high  degree  of  cross-reactions  in the IgM and  IgG assays
could  lead  to  false-positive  results.57 In countries  where
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Figure  3  Diagnostic  algorithm  for  detecting  Zika  virus  and  related  arbovirus.  This  algorithm  is  adapted  from  the  one  proposed
by the  Pan  American  Health  Organization.65 Due  to  cross-reactivity  in secondary  Flavivirus  infections,  ELISA  for  IgM against  Dengue
virus is  suggested.  NS1:  non-structural  protein  1;  RT-PCR:  real-time  polymerase  chain  reaction;  DENV:  dengue  virus;  ZIKV:  Zika  virus;
CHIKV: chikungunya  virus;  IgM: immunoglobulin  M.
laboratory  capacities  are  limited,  the arbovirus  diagnosis
is  often  performed  by  serologic  testing  by  IgM  ELISA  or
rapid  tests.  If rapid tests  are used  for  dengue,  it is  recom-
mended  to  use  a combined  NS1  antigen  and  IgM  antibody  test
to  increase  the  sensitivity  and  specificity  of  dengue  fever
diagnosis.58 If  several  patients  are negative  to  a DENV  NS1
test  within  the first  week  of  a ‘‘dengue-like  disease,’’  the
Zika  virus  disease  or  other  arboviruses  should  be  suspected.
In countries  with  advanced  laboratory  capacities,  a RT-PCR
assay  should  be  the first-line  test.  Patients  within  the acute
phase  of  infection  with  a dengue  or  chikungunya-like  syn-
drome,  or  fever  and  rash,  with  negative  DENV  and  CHIKV
RT-PCR  assays  should  be  tested  with  a specific  ZIKV  RT-PCR
assay.57 The algorithm  for  Zika  virus  detection  in Fig.  3 can
be  a  useful  guide  for  clinicians.
There  are  two  strategies  for  the  molecular  detection
of  ZIKV.  One  is  the  detection  of Flaviviruses  using  consen-
sus  primers  and  posterior  detection  of  specific  ZIKV  ARN.59
The  other  strategy  is  to  use  specific  ZIKV primers  and
probes.  Several  protocols  have been  developed  to target  the
E-encoding  gene,60 the  membrane-envelope  junction  (M/E-
encoding  gene),  the  partial  envelope  (pE)-encoding  gene,
and the NS5-encoding  gene.61,62 Furthermore,  ZIKV  RT-PCR
do  not cover  the genetic  diversity  and  geographic  distri-
bution  of all  ZIKV strains.61 The  reason  is  that  the primers
and  probes  have  been  designed  using  only the few full  ZIKV
genome  sequences  available.  On March  17,  2016,  the FDA
issued  an  Emergency  Use  Authorization  (EUA)  to  authorize
the  emergency  use  of  the  CDC’s  Trioplex  Real-time  RT-PCR
Assay  for  the qualitative  detection  and  differentiation  of
RNA  from  the Zika  virus,  dengue  virus,  and  chikungunya  virus
in  human  sera  or  cerebrospinal  fluid,  and  for  the qualitative
detection  of  Zika  virus  RNA in urine  and  amniotic fluid.63 On
April  28,  2016,  Focus  Diagnostics,  Inc.’s  Zika Virus RNA  Qual-
itative  Real-Time  RT-PCR  test  was  authorized  under  the EUA
for  the  qualitative  detection  of  RNA  from  the  Zika virus  in
human  serum  specimens.  This  is  the  first  commercial  test  to
detect  the  Zika  virus  that  has  been  authorized  by  the FDA
for  emergency  use.63
Zika virus  serology  is usually  performed  by  ELISA,  with
confirmation  by a  plaque  reduction  neutralization  test
(PRNT,  which  is  the  ‘‘gold  standard’’  for  anti-Flavivirus  anti-
body  differentiation)  according  to  standard  protocols.  How-
ever,  PRNT  is  done  only  in  highly  specialized  laboratories,
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is  expensive,  and  may  require  regulated  laboratories
because  of the manipulation  of live  viruses.64 To  date,  there
is  no  validated  commercial  serology  kit  for  ZIKV,  but  on
February  26, 2016,  the  FDA  issued  an Emergency  Use  Autho-
rization  for  the  emergency  use  of  CDC Zika  Immunoglobulin
M  Antibody  Capture  Enzyme-Linked  Immunosorbent  Assay
(Zika  MAC-ELISA)  for  the  presumptive  detection  of Zika
virus-specific  IgM in human  sera or  cerebrospinal  fluid.63
Samples  for serologic  or  molecular  testing  should  have  spe-
cial  storage  conditions,  ranging  from  refrigeration  (2--8 ◦C)
to  freezing  (−10  to −20 ◦C or  −70 ◦C)  depending  of the time
and  site  of  testing.65
Treatment
Similar  to other  arboviral  diseases,  there  is  no  specific
antiviral  drug treatment  for  ZIKV  infection.  Symptomatic
treatment  is  recommended  after  excluding  more  serious
conditions  like  malaria,  dengue,  and  bacterial  infections.  In
acute  infection,  treatment  is  symptomatic  and  supportive,
consisting  of  rest  and  the  use  of  acetaminophen  to  relieve
fever  (<4  g/day).  The  use  of  ibuprofen,  naproxen,  or  another
non-steroidal  anti-inflammatory  agents  (NSAID)  to  relieve
the  arthritic  component  of  the disease  can be used when
dengue  infection  is  discarded.  Patients  should  be advised  to
drink  plenty  of  fluids  to  replenish  fluid  lost from  sweating,
vomiting,  and  other  insensible  losses.66
There  are  specific  guidelines  for  health  care providers
caring  for  infants  and children  with  possible  Zika  virus
infection  at the  official  CDC  website.  These  guidelines
recommend  clinical  evaluation  and  laboratory  testing  for
infants  with  possible  congenital  Zika  virus  infection,  with
or  without  microcephaly  or  intracranial  calcifications.67
The  CDC  has  also  put  out  guidelines  for health  care
providers  caring  for  women  of  reproductive  age  with  pos-
sible  Zika  virus  exposure.  Women  who  have had Zika  virus
disease  or exposure  without  clinical  illness,  should  wait  at
least  8 weeks  after symptom  onset  to  attempt  conception.
Men  with  Zika  virus  disease  should  wait  at least  6  months
after  symptom  onset,  or  8  weeks  after exposure  to  the virus
without  clinical  illness,  to  attempt  conception.  These  guide-
lines  also  provide  updated  recommendations  for  the testing
of  pregnant  women  with  possible  Zika  virus  exposure.68 It is
important  to  note that  the current  guidance  is  based  on  a
limited  body  of  evidence.
Prevention
Pending  vaccine  development,  the  only  effective  preventive
measures  consist  of  individual  protection  against  mosquito
bites  and  vector  control.  Control  of  both  adult and  larval
mosquito  populations  uses the same  model  as  for dengue
and  has  been  relatively  effective  in many  countries  and
settings.  Mosquito  control  is  the best  available  method  for
preventing  ZIKV  infection.  Breeding  sites  must  be  removed,
destroyed,  frequently  emptied,  and  cleaned  or  treated  with
insecticides.43
For  protection,  clothing  which  minimizes  skin  exposure
to  the  day-biting  vectors  is  advised.  Repellents  can  be
applied  to exposed  skin  or  to  clothing,  in  strict  accor-
dance  with  product  label  instructions.  Repellents  should
contain  DEET  (N,  N-diethyl-3-methylbenzamide),  IR3535
(3-[N-acetyl-N-butyl]-aminopropionic  acid  ethyl  ester)  or
icaridin  (1-piperidinecarboxylic  acid, 2-(2-hydroxyethyl)-
1-methylpropylester).  Mosquito  coils  or  other  insecticide
vaporizers  may  also  reduce  indoor  biting.69
As  previously  mentioned,  the correct  and consistent  use
of  condoms  during  any  sexual  intercourse  is  encouraged  to
prevent  the sexual  transmission  of  the  Zika  virus.  Another,
although  difficult,  option  is  sex abstention  while  active  virus
transmission  persists.36
Vaccines
Up  to  March,  2016  there  is no available  vaccine  against  the
Zika  virus.  There  are several  proposals  for  a  vaccine,  using
the  same  methodology  as  other  anti-flaviviruses  vaccines70;
nevertheless,  the  process  is  still  long.  There  are  ethical
issues  involving  pregnant  women  and the ‘‘safe  use’’  of
vaccines,  which are still  a  barrier.71
Future  directions
There  are still  many  unanswered  questions  regarding  the
Zika  virus  disease.  Clinical  and epidemiological  studies  must
be performed  to  describe  viral  dynamics  and  the expansion
of  the  outbreak.  More  studies  are  needed  to  confirm  the
suspected  association  between  ZIKV  infection  with  micro-
cephaly  and  Guillain--Barré  syndrome.  Research  must  be
done  to  identify an antiviral,  prophylactic,  or  immunother-
apy vaccine  as  well  as  diagnostic  ELISA  testing.
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